Ono Pharmaceutical Company, Ltd.
76 articles with Ono Pharmaceutical Company, Ltd.
Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries
Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced it has entered into an exclusive license agreement with Ono Pharmaceutical Co., Ltd., for the development and commercialization of RBN-239
AGC Biologics Enters into Partnership as a CDMO with Ono Pharmaceuticals to Manufacture Biopharmaceuticals at Clinical Development Stage
AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with Ono Pharmaceutical Co., Ltd. (ONO) to manufacture new, innovative biopharmaceuticals at the clinical development stage. ONO is a R&D-oriented pharmaceutical company committed to discovering and developin
Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Co. have teamed up to study the most common type of metastatic colorectal cancer (mCRC).
Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.
Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, and Ono Pharmaceutical Co., Ltd. today announced an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47.
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
The decision, which is likely to be appealed, will allow Dana-Farber to license the technology.
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
Ono Pharmaceutical Co., Ltd. announced that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.
Repare Therapeutics Announces a Strategic Partnership Agreement With ONO Pharmaceutical Co., Ltd. for Repare’s Polθ Inhibitor Program in Japan and Selected Territories in Asia
Repare Therapeutics, Inc. announced that it has entered into an exclusive strategic research, development and commercialization partnership with ONO Pharmaceutical Co., Ltd., for Repare’s small molecule Polθ inhibitor program in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries, excluding mainland China.
This second collaboration involves the discovery of candidate MAbs against an undisclosed target and leverages the power of Integral Molecular's MPS Antibody Discovery platform.
Neurimmune today announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered into a collaboration focused on the development of human-derived antibodies against a novel therapeutic target for neurodegenerative diseases.
Array BioPharma, Inc. secured approval for its combination treatment for BRAF-mutant metastatic melanoma.
Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study
Opdivo plus low-dose Yervoy is the first and only FDA-approved Immuno-Oncology combination therapy for this patient population.
The companies will also collaborate on discovery efforts to identify additional compounds from Ono’s PGE2 receptor antagonist programs.
Cyclenium will receive an upfront payment and research funding from Ono, as well as development milestones and royalties on marketed products.
Under the deal, Neurimmune will conduct research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine technology platform.
Array BioPharma And Ono Pharma Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib